Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JWCAR029 in Relapsed/Refractory Mantle Cell Lymphoma
CTR20202358Phase 2Completed
- Sponsor
- Shanghai Mingju Biotechnology
- Start
- Nov 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of relmacabtagene autoleucel in mantle cell lymphoma (MCL), sponsored by Shanghai Mingju Biotechnology. Started Nov 2020; status: completed.
02
Drugs
relmacabtagene autoleucel
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20202358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202358.